Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $4.2 million.

  • Zevra Therapeutics' Free Cash Flow rose 12290.39% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.2 million, marking a year-over-year increase of 6520.93%. This contributed to the annual value of -$69.7 million for FY2024, which is 10592.06% down from last year.
  • Per Zevra Therapeutics' latest filing, its Free Cash Flow stood at $4.2 million for Q3 2025, which was up 12290.39% from -$3.8 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Free Cash Flow peaked at $16.5 million during Q2 2021, and registered a low of -$19.1 million during Q2 2024.
  • In the last 5 years, Zevra Therapeutics' Free Cash Flow had a median value of -$4.5 million in 2022 and averaged -$6.3 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Free Cash Flow skyrocketed by 65220.76% in 2021, and later plummeted by 41976.88% in 2022.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Free Cash Flow stood at -$865000.0 in 2021, then crashed by 419.77% to -$4.5 million in 2022, then crashed by 260.99% to -$16.2 million in 2023, then fell by 0.12% to -$16.2 million in 2024, then soared by 125.57% to $4.2 million in 2025.
  • Its last three reported values are $4.2 million in Q3 2025, -$3.8 million for Q2 2025, and -$8.3 million during Q1 2025.